Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy

Japanese Journal of Clinical Oncology

Volumn 43, Issue 9, 2013, Pages 923-928

  Taguchi, Satoru ^a   Nakagawa, Tohru ^a   Hattori, Mami ^a   Niimi, Aya ^a   Nagata, Masayoshi ^a   Kawai, Taketo ^a   Fukuhara, Hiroshi ^a   Nishimatsu, Hiroaki ^a   Ishikawa, Akira ^a   Kume, Haruki ^a   Homma, Yukio ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Bladder cancer; Chemotherapy; Metastasectomy; Prognostic factor; Urothelial carcinoma

Indexed keywords

ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; HEMOGLOBIN; IFOSFAMIDE; LACTATE DEHYDROGENASE; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL PREDICTION; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; VISCERAL METASTASIS;

BLADDER CANCER; CHEMOTHERAPY; METASTASECTOMY; PROGNOSTIC FACTOR; UROTHELIAL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; KIDNEY NEOPLASMS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY;

EID: 84883390013     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt096     Document Type: Article

References (15)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer incidence and mortality worldwide. IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer 2010. http://globocan.iarc.fr.
2. Matsuda T, Marugame T, Kamo KI, et al. Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2012;42:139-47.
3. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989;64:2448-58.
4. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
5. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602-8.
6. Takahashi S, Suzuki M, Kume H, et al. Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. Jpn J Clin Oncol 2005;35:79-83.
7. Matsuo S, Imai E, Hishida A, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-92.
8. Eisenhauer EA, Therasse P, Verweij J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
9. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173-81.
10. Abe T, Shinohara N, Nonomura K, et al. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur Urol 2007;52:1106-14.
11. Nakagawa T, Hara T, Kawahara T, et al. Prognostic risk stratification of patients with urothelial carcinoma of the urinary bladder who developed recurrence after radical cystectomy. J Urol 2013; 189:1275-81.
12. Flanigan RC. Urothelial tumors of the upper urinary tract. In: Wein AJ, Kavoussi LR, Novick AC, et al., editors. Campbell-Walsh Urology, 9th edn. Philadelphia: WB Saunders 2007;1638-52.
13. Lehmann J, Suttmann H, Albers P, et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol 2009;55:1293-9.
14. Herr HW, Donat SM, Bajorin DF, et al. Bladder cancer, the limits of surgical excision-when/how much?. Urol Oncol 2001;6:221-4.
15. Herr HW. Is metastasectomy for urothelial carcinoma worthwhile?. Eur Urol 2009;55:1300-1.